Trial Profile
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Lipohypertrophy
- Focus Adverse reactions
- Sponsors Theratechnologies
- 10 Sep 2018 Status changed from active, no longer recruiting to discontinued.
- 01 Jun 2018 Planned End Date changed from 1 Mar 2030 to 1 Jul 2018.
- 01 Jun 2018 Status changed from recruiting to active, no longer recruiting.